Mardi Dier - Oct 12, 2021 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
CFO & Executive Vice President
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Oct 12, 2021
Transactions value $
-$552,524
Form type
4
Date filed
10/14/2021, 06:33 PM
Previous filing
Jun 22, 2021
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale -$288K -3.48K -7.64% $82.79 42K Oct 12, 2021 Direct F1
transaction RARE Common Stock Sale -$265K -3.26K -7.76% $81.16 38.8K Oct 14, 2021 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
F2 The transaction reported in this row on this Form 4 was effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.55 to $81.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.